ArticleCancers2020
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 6 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis.Scientific reports · 2024Pooled it
- C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.Critical reviews in oncology/hematology · 2024Pooled it
- Prognostic significance of the modified Glasgow Prognostic Score in NSCLC patients undergoing immune checkpoint inhibitor therapy: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.International journal of molecular sciences · 2023Pooled it
- A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.Cancer medicine · 2023Pooled it
- The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Radiotherapy-induced abscopal effects in immune checkpoint inhibitor-refractory metastatic disease: results from a large multicenter real-world cohort study.Oncoimmunology · 2026Article
- Review
- Article
- Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annual review of immunology · 2026Review
- Phenotypic age acceleration and early-onset lung cancer: a case-control and prognostic cohort study involving multiple clinical centres with validation in the UK Biobank.EBioMedicine · 2026Article
- Lymphocyte-to-C-reactive protein ratio predicts prognosis in unresectable locally advanced non-small cell lung cancer patients.Annals of medicine · 2025Article
- Prognostic Value of Routine Hematological Markers and ECOG Performance in Predicting Overall Survival in Lung Cancer-A Retrospective Cohort Study and Literature Review.Journal of clinical medicine · 2025Article
- Leveraging Artificial Intelligence and Modulation of Oxidative Stressors to Enhance Healthspan and Radical Longevity.Biomolecules · 2025Review
- The association between serum uric acid and survival outcomes in patients with metastatic renal cell carcinoma treated with targeted therapy.BMC cancer · 2025Article
- The modified-Gustave Roussy immune score: assessing immune prognosis in advanced gastric cancer patients at baseline.Future oncology (London, England) · 2025Article
- Blood-Based Inflammatory Markers Are Associated with Treatment Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Anti-PD-1 Therapy: CRP as a Superior Predictive Marker.International journal of molecular sciences · 2025Article
- Thromboinflammatory Biomarkers Are Early Predictors of Disease Progression in Non-Small Cell Lung Cancer Patients.Cancers · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiomarkers for predicting response to immune checkpoint inhibitors (ICI) are scarce and often lack external validation. This study provides a comprehensive investigation of pretreatment C-reactive protein (CRP) levels as well as its longitudinal trajectories as a marker of treatment response and disease outcome in patients with advanced non-small cell lung cancer (NSCLC) undergoing immunotherapy with anti PD-1 or anti PD-L1 agents.
methodsWe performed a retrospective bi-center study to assess the association between baseline CRP levels and anti PD-(L)1 treatment outcomes in the discovery cohort (
resultsIn the discovery cohort, elevated pretreatment CRP levels emerged as independent predictors of worse PFS (HR per doubling of baseline CRP = 1.37, 95% CI: 1.16-1.63,
conclusionThese findings support the concept that CRP should be further explored by future prospective studies as a simple non-invasive biomarker for assessing treatment benefit during anti PD-(L)1 treatment in advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.